23andMe Holding Co. (ME) Financial Statements (2026 and earlier)

Company Profile

Business Address 870 MARKET STREET
SAN FRANCISCO, CA 94102
State of Incorp.
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
3/31/2025
12/31/2024
MRQ
3/31/2024
3/31/2023
3/31/2022
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments38,24879,350216,488386,849553,182788
Cash and cash equivalent38,24879,350216,488386,849553,182788
Restricted cash and investments7,7461,6641,3991,3991,599 
Receivables2,73112,3059,0751,8973,380 
Inventory, net of allowances, customer advances and progress billings15,55821,40712,46510,24710,789 
Inventory15,55821,40712,46510,24710,789 
Prepaid expense8,82711,6749,296  449
Deferred costs5,1739,9204,7925,3767,700 
Disposal group, including discontinued operation  1,057    
Other current assets2,8262,6061,794   
Other undisclosed current assets21,59821,594 19,22425,139 
Total current assets:102,707161,577255,309424,992601,7891,237
Noncurrent Assets
Operating lease, right-of-use asset53335,01348,89456,07855,577 
Property, plant and equipment1,25819,22628,35138,60849,851 
Intangible assets, net (including goodwill)25,33527,31533,255397,264425,649 
Goodwill    351,744351,744 
Intangible assets, net (excluding goodwill)25,33527,31533,25545,52073,905 
Asset, held-in-trust      508,645
Restricted cash and investments5,30012,2746,9746,9746,974 
Disposal group, including discontinued operation, noncurrent assets  481    
Other noncurrent assets5,3658121,8683,0212,593 
Other undisclosed noncurrent assets19,39620,72420,51615,6619,635 
Total noncurrent assets:57,187115,845139,858517,606550,279508,645
TOTAL ASSETS:159,894277,422395,167942,5981,152,068509,882
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,04874,70753,83479,35482,51832
Accounts payable5497,78111,57112,92437,930 
Accrued liabilities15,49966,92642,26366,43044,58832
Deferred revenue49,34762,91964,82762,52162,939 
Debt     1,500
Deferred compensation liability      17,799
Restructuring reserve   22   
Disposal group, including discontinued operation  9,823    
Other undisclosed current liabilities7,3085,8918,6487,5417,784 
Total current liabilities:72,703153,340127,331149,416153,24119,331
Noncurrent Liabilities
Long-term debt and lease obligation:     78,524 
Liabilities, other than long-term debt42961,36279,31679,2434,647 
Deferred revenue   10,000   
Disposal group, including discontinued operation, liabilities  4,925    
Other liabilities2241,7841,4711,4804,647 
Operating lease, liability20554,65367,84577,76378,524 
Other undisclosed noncurrent liabilities113,504     
Total noncurrent liabilities:113,93361,36279,31679,24383,171 
Other undisclosed liabilities      68,785
Total liabilities:186,636214,702206,647228,659236,41288,116
Equity
Equity, attributable to parent, including:(26,742)62,720188,520713,939915,6565,000
Common stock334946451
Additional paid in capital2,427,2282,417,3432,361,5592,220,8972,110,16053,601
Accumulated other comprehensive income (loss)    (620)179 
Accumulated deficit(2,453,973)(2,354,626)(2,173,088)(1,506,384)(1,194,728)(48,603)
Other undisclosed equity, attributable to parent      1
Other undisclosed equity      416,766
Total equity:(26,742)62,720188,520713,939915,656421,766
TOTAL LIABILITIES AND EQUITY:159,894277,422395,167942,5981,152,068509,882

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
3/31/2025
12/31/2024
TTM
3/31/2024
3/31/2023
3/31/2022
12/31/2020
Revenues189,896144,747219,638299,489271,893 
Revenue from related parties47,44846,064 
Cost of revenue(89,892)(62,000)(120,261)(164,993)(138,948) 
Gross profit:100,00482,74799,377134,496132,945 
Operating expenses(340,644)(251,743)(780,845)(458,507)(387,098) 
Operating income (loss):(240,640)(168,996)(681,468)(324,011)(254,153) 
Nonoperating income (expense)1,021312506(93)(83) 
Investment income, nonoperating   (2,375)   
Gain on contract termination     15 
Income (loss) from continuing operations before equity method investments, income taxes:(239,619)(168,684)(680,962)(324,104)(254,236) 
Other undisclosed income (loss) from continuing operations before income taxes 5,86514,3319,67633,266 
Income (loss) from continuing operations before income taxes:(239,619)(162,819)(666,631)(314,428)(220,970) 
Income tax expense (benefit)4141(73)2,7723,480 
Income (loss) from continuing operations:(239,578)(162,778)(666,704)(311,656)(217,490) 
Loss before gain (loss) on sale of properties:(217,490)
Net income (loss):(239,578)(162,778)(666,704)(311,656)(217,490) 
Other undisclosed net loss attributable to parent(41,307)(18,760)    
Net income (loss) available to common stockholders, diluted:(280,885)(181,538)(666,704)(311,656)(217,490) 

Comprehensive Income ($ in thousands)

6/30/2025
TTM
3/31/2025
12/31/2024
TTM
3/31/2024
3/31/2023
3/31/2022
12/31/2020
Net income (loss):(239,578)(162,778)(666,704)(311,656)(217,490) 
Other comprehensive income (loss)   620(799)179 
Other undisclosed comprehensive loss      
Comprehensive income (loss):(239,578)(162,778)(666,084)(312,455)(217,311) 
Other undisclosed comprehensive loss, net of tax, attributable to parent(41,307)(18,760)    
Comprehensive income (loss), net of tax, attributable to parent:(280,885)(181,538)(666,084)(312,455)(217,311) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: